Cover Image
市場調查報告書

T細胞免疫療法市場

T-Cell Immunotherapy Market, 2017-2030 (2nd Edition)

出版商 ROOTS ANALYSIS 商品編碼 342155
出版日期 內容資訊 英文 654 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
T細胞免疫療法市場 T-Cell Immunotherapy Market, 2017-2030 (2nd Edition)
出版日期: 2017年01月13日 內容資訊: 英文 654 Pages
簡介

免疫療法的概念追溯到18世紀,不過,這個領域完成顯著的演進,在製藥產業是成長最快速的部門之一。受免疫查核點抑制劑的初期的成功推動,T細胞免疫療法,成為創新且強力的武器。

本報告提供T細胞免疫療法市場相關調查分析,以目前的市場情勢與未來的可能性為焦點,提供主要企業,開發中產品的開發階段,聯盟的動向,創新的技術,治療領域,競爭情形等系統性資訊。

第1章 序文

第2章 摘要整理

第3章 簡介

第4章 市場形勢

  • 概要
  • T細胞免疫療法:形勢的演進
  • T細胞免疫療法:有前途的開發平台
  • T細胞免疫療法:各產品類型的候補藥
  • T細胞免疫療法:各開發業者類型的候補藥
  • T細胞免疫療法:各開發階段的候補藥
  • T細胞免疫療法:標的腫瘤適應
  • T細胞免疫療法:主要的產業企業
  • T細胞免疫療法:主要的產業以外的企業
  • T細胞免疫療法:CAR-T、TCR療法上最受歡迎的標的

第5章 嵌合抗原受體表現T (CAR-T) 細胞療法

  • 簡介
  • 開發的過程
  • 研究現況
  • 嵌合抗原受體的解剖學配置
  • 嵌合抗原受體的開發
  • CAR-T細胞的開發
  • 通用CAR-T細胞
  • 給藥途徑
  • 毒性問題
  • 毒性問題的對應
  • CD19:富有魅力的標的
  • 其他標的
  • CAR-T療法的課題
  • CTL019 (Novartis)
  • JCAR (Juno Therapeutics)
  • KTE-C19 (Kite Pharma)
  • CAR-T Series (Cellular Biomedicine Group)
  • CD19 CAR (TaKaRa BIO)

第6章 T細胞受體 (TCR) 基礎療法

  • 簡介
  • T細胞受體結構
  • CAR和TCR的差異
  • 開發的過程
  • 研究現況
  • 作用機制
  • 安全性的問題
  • 抗原特異性T細胞受體的必要條件
  • 強化抗腫瘤效果的策略的明確化
  • SPEAR T-Cells (Adaptimmune)
  • ALT-801 (AltorBioScience)
  • IMCgp100 (Immunocore)
  • JTCR016 (Juno Therapeutics)
  • WT1 TCR Gene Therapy (Cell and Gene Therapy Catapult)

第7章 腫瘤浸潤淋巴球 (TIL) 基礎療法

  • 簡介
  • 開發的過程
  • 研究現況
  • 提高功效的研究策略
  • 預後診斷工具
  • 製造工程
  • LN-144 (Lion Biotechnologies)
  • TIL (Nantes University Hospital)
  • TIL (Netherlands Cancer Institute)

第8章 市場機會

  • 概要
  • 範圍與限制
  • 預測手法
  • T細胞免疫療法市場全體
  • CAR-T療法市場全體
  • TCR療法市場全體
  • TIL療法市場全體

第9章 T細胞療法的主要治療領域

  • 概要
  • 簡介
  • 骨髓惡性腫瘤
    • 白血病和淋巴瘤
    • 多發性骨髓瘤
  • 固態腫瘤
    • 轉移性黑色素瘤
    • 肺癌
    • 膀胱癌
    • 腎臟癌
    • 卵巢癌
    • 乳癌

第10章 新興技術

  • 概要
  • 簡介
  • 基因編輯技術:簡介
  • 基因編輯技術:應用
  • 特性改善的T細胞療法的設計

第11章 社群媒體:新興趨勢

  • 概要
  • Twitter趨勢

第12章 夥伴關係和合作

  • 概要
  • 夥伴關係模式
  • 最近的聯盟

第13章 創業投資的支援

  • 概要
  • T細胞免疫療法:資金籌措範例

第14章 其他T細胞免疫療法

  • 概要
  • 其他T細胞免疫療法

第15章 案例研究:細胞療法的製造

第16章 案例研究:原價分析

第17章 企業簡介

  • 概要
  • Adaptimmune
  • AltorBioScience
  • bluebird Bio
  • Cellectis
  • Cellular Biomedicine Group
  • Immunocore
  • Juno Therapeutics
  • Kite Pharma
  • Lion Biotechnologies
  • Novartis
  • TaKaRa BIO
  • Unum Therapeutics

第18章 採訪

第19章 結論

第20章 附錄1:表格形式的資料

第21章 附錄2:企業、組織清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: RA10074

The concept of immunotherapies dates back to the 18th century; however, since inception, the field has evolved tremendously and is currently cited as one of the most rapidly growing segments of the pharmaceutical industry. Harnessing immune system components for developing therapeutic solutions has demonstrated significant clinical benefit for various diseases areas, specifically against a number of oncological indications. Immunotherapeutics have gradually gained a strong foothold in the pharmaceutical industry. Post the early success of immune checkpoint inhibitors, T-cell immunotherapy has emerged as another innovative and potent arm of this market.

Adoptive immunotherapy is an emerging concept that involves the passive transfer of immune cells, which may or may not be modified / genetically altered to express a desired set of traits and / or features.Characterized by key features such as target specificity, adaptability and the capability to retain immunologic memory, T-cells have been effectively used as therapeutic tools to mediate an artificial immune response. More specifically, T-cell immunotherapies are classified into three major segments, namely chimeric antigen receptor (CAR) T-cell, T-cell receptor (TCR) and tumor infiltrating lymphocyte (TIL) based therapies. Academicians across the globe have significantly contributed to this field by convening the initial research on potential product candidates; this has served as the intellectual framework for establishment of several start-ups and evolution of the product portfolios of established players in the industry.

The overall market is expected to witness a significant growth in opportunities for a variety of stakeholders in the coming decade. It is important to highlight that various technology providers, aiming to develop and / or support the development of T-cell immunotherapy products with improved efficacy and safety, have designed and introduced advanced platforms for engineering of T-cells. Innovation in this domain, backed by lucrative rounds of venture capital (VC) funding, has led to the discovery of several novel molecular targets and strengthened the research pipelines of companies focused in this space. The capability to target diverse therapeutic areas is amongst the most prominent growth drivers of this market.

Synopsis

The "T-Cell Immunotherapy Market, 2017-2030 (2nd edition) " report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. Immuno-oncology has been gradually nurtured by researchers over the last several years and is now considered as the fourth major pillar of cancer therapy, after surgery, chemotherapy and radiotherapy. As indicated earlier, the T-cell therapy market has evolved significantly over the last few years, offering promising opportunities for a variety of stakeholders. The domain is characterized by a robust and opportunistic pipeline of product candidates focused on targeting hematological cancers and solid tumors. However, with no marketed products, this emerging field is still in its infancy. The report provides a comprehensive overview of the market, focusing particularly on CAR-T therapies, TCR therapies and TIL therapies.

The role of academic players / research institutes has been critical in this domain. Post the establishment of initial proof-of-concept, several industry players have entered into collaboration with non-industry participants to fund the clinical and commercial development of potential product candidates. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis / University of Pennsylvania), KTE-C19 and HPV-16 E6 TCR (Kite Pharma / National Cancer Institute), and LN-144 (Lion Biotechnologies / National Cancer Institute). As mentioned before, encouraging clinical results have significantly accelerated the progress of these therapies.

Several technology providers, especially those with capabilities in genome editing, and viral and non-viral gene transfer, are also actively involved in this emerging market. Many of these players have entered into partnerships with therapy developers in order to assist in designing novel features to enhance the efficacy and potency of existing T-cell therapies. A prominent example of such a technology is safety switches; these are innovative molecular tools designed to manage known side effects, such as cytokine release syndrome and B-cell aplasia, by allowing control over the expression of certain genes in the engineered cell population.

One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing programs of both small and big pharmaceutical firms in this domain. It is worth mentioning that there is a lot of hope pinned on multiple start-ups, which have received significant backing by several strategic investors and venture capital firms. Amongst other elements, the report elaborates on the following areas:

  • The current state of the market with respect to key players, developmental stages of pipeline products (both clinical / preclinical) and target therapeutic indications. In addition, we have also provided an overview of the competitive landscape, key challenges and anticipated future trends within the three major types of T-cell based therapies.
  • Detailed profiles of candidate therapies that are in the mid to late stages of development (phase I/II or above).
  • The partnerships that have been established in the recent past, covering research and development collaborations, manufacturing agreements, license agreements specific to technology platforms, product development / commercialization agreements, clinical trial collaborations and joint venture agreements.
  • Details of innovative technological platforms, such as safety switches, which have contributed significantly in overcoming existing gaps in the therapeutic regimen.
  • An analysis of the various investments, grants and other types of funding provided to companies focused in this area.
  • An overview of the various therapeutic areas being addressed by therapy developers, including an assessment of the opportunity offered by both oncological and non-oncological disease indications.
  • A discussion on the emerging trends on social media and on the popularity of T-cell immunotherapy products on Twitter over the last few years.
  • Details on novel T-cell immunotherapies that are being investigated, along with their respective mechanisms of action.
  • A detailed case study on the manufacturing of cell therapy products, highlighting key challenges and a list of contract service providers and in-house manufacturers that are involved in this space.
  • A discussion on the development and sales potential based on target consumer segments, likely adoption rates and expected pricing based upon different models / approaches.

With most products still in the early stages of clinical development, we have provided informed estimates of the potential future sales of different CAR-T, TCR and TIL therapies. The research, analysis and insights presented in this report are backed by a deep understanding of the key drivers behind the predicted growth. We have provided three market forecast scenarios to add robustness to our model. More specifically, the conservative, base and optimistic forecast scenarios represent three different tracks of the industry's evolution, taking into account the ambiguities associated with the development and approval of pharmaceutical products. All actual figures have been sourced from publicly available information. All figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1. During the course of our research, we identified around 280 T-cell therapies being evaluated across various phases of development. Among these, CAR-T cell products are the most common (67%), followed by TCR (23%) and TIL (10%) based therapies.
  • 2. Overall, 29% of the pipeline therapies are being evaluated in phase II / phase III clinical trials; on the other hand, 38% of the therapies are in the preclinical / discovery stage of development. Examples of promising late-stage therapies include CTL-019 (Novartis), JCAR015 (Juno Therapeutics), KTE-C19 and HPV-16 E6 TCR (Kite Pharma), NY-ESO-1 TCR (Adaptimmune / GSK), LN-144 (Lion Biotechnologies), ALT801 (Altor BioScience) and IMCgp100 (Immunocore).
  • 3. Academic institutions are the leading innovators in this domain. Many universities and research institutes have made significant contributions by investing time and building expertise in the design and development of novel CAR-Ts, TCRs and TILs. We observed that non-industry players are involved in the development of around 50% of all the therapies currently in the pipeline. The most active non-industry players (based upon the number of therapies under development) include the National Cancer Institute, MD Anderson Cancer Center, Baylor College of Medicine, University of Pennsylvania, Chinese PLA General Hospital, Southwest Hospital, Fred Hutchinson Cancer Research Center, Fuda Cancer Hospital, Memorial Sloan Kettering Cancer Center, Uppsala University and City of Hope Medical Center.
  • 4. The market is highly fragmented and characterized by the presence of several start-ups, small pharma and big pharma firms.The key players involved in development of T-cell therapies (based upon the number of candidate therapies in their respective product pipelines) include Juno Therapeutics, Shanghai Genechem, Kite Pharma, Cellular Biomedicine Group, Lion Biotechnologies, Takara Bio, Celgene, Adaptimmune and ZIOPHARM Oncology. AURORA BioPharma, Beijing Doing Biomedical, Bellicum Pharmaceuticals, CARsgen Therapeutics, iCarTABBioMed, Intrexon, Mustang Bio, Novartis, Sinobioway Cell Therapy, Unum Therapeutics and Shionogi are other players that have more than one clinical stage therapies.
  • 5. In addition to some of the companies outlined above, there are several other start-ups that are focused in this domain; these include (in alphabetical order) Altor BioScience, Autolus, Adicet Bio, Catapult Therapy TCR, Chimeric Therapeutics, Formula Pharmaceuticals, Gadeta, Immatics US, JW Biotechnology, Lion TCR, Leucid Bio, Mustang Therapeutics, Poseida Therapeutics, TILT Biotherapeutics, TNK Therapeutics, Tmunity Therapeutics and Vor Biopharma.
  • 6. Stakeholders have forged synergistic partnerships in order to exploit the commercial potential of their respective assets. Overall, we identified more than 135 partnerships that have been inked in the T-cell immunotherapy field over the period 2005-2016. Most common forms of partnerships were related to research (20%), followed by technology licensing (15%), product discovery, development and commercialization (12%), manufacturing (11%), clinical trials (7%) and acquisitions (7%).
  • 7. Amidst several challenges, including the complexities associated with manufacturing cell-based products, and competition from existing drug / therapy classes (such as monoclonal antibodies, bi-specific antibodies and immune checkpoint inhibitors), therapy developers are engaged in extensive research in order to effectively deal with these issues. Several contract manufacturing organizations with advanced capabilities have emerged to provide manufacturing services for the personalized T-cell based therapies. Examples of the CMOs providing manufacturing services for T-cell therapies include apcethBiopharma, Atlantic Bio GMP, Cell and Gene Therapy Catapult, Cell Therapies, CELLforCURE, Cellular Therapeutics, MolMed and PCT (a Caladrius company).
  • 8. A number of technological advancements have taken place in order to support the development of these therapies; engineered CAR-Ts with switch technologies are amongst the latest additions to next-generation T-cell immunotherapies. Funding from VC firms and strategic investors has been a key enabler to the market's growth. Notably, close to USD 5 billion has been invested in this domain over the past few years. Several big ticket investments have recently taken place. For instance, Immunocore raised USD 320 million in July 2015, Kite Pharma raised USD 288 million in December 2015 and Cellectis raised USD 228 million in March 2015.
  • 9. A variety of novel types of immunotherapies, other than CAR-T, TCR and TIL, are expected to emerge in the mid-long term. Companies such as TxCell, Caladrius Biosciences, TRACT Therapeutics, Green Cross Cell and Tmunity Therapeutics, are developing T-regulatory cell based therapies. Other players, namely Opexa Therapeutics, TVAX and Immunovative Therapies, are developing T-cell based vaccines for treating autoimmune disorders and various forms of cancer. Further, Atara Biotherapeutics, Cell Medica and Tessa Therapeutics are working on the development of virus-driven T-cell therapies. A number of companies have developed unique technology platforms based on T-cells. Examples include Targazyme (Fucosylated T-cells), Triumvira (TAC-T cells), Chengdu MedGenCell (PD-1 Knockout Engineered T-cells) and GammaCell Bio-Technologies (γδ T-cells).
  • 10. Overall, we believe the T-cell therapy market is likely to be worth USD 25 billion by 2030, expanding at an annualized growth rate of over 101% during this time period. Specifically, by 2030, the markets for CAR-T and TCR therapies market are likely to be worth over USD 11 billion each.Product candidates, such as KTE-C19, CTL019, NY-ESO-1 TCR, ALT 801 and JCAR017, are expected to emerge as potential blockbusters in the long term.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information. The various secondary sources of information that we use include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 presents an executive summary of the report. It offers a high level view on where the T-cell immunotherapy market is headed in the mid-long term.

Chapter 3 provides a general introduction to T-cell immunotherapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of oncological indications, the advent of cancer immunotherapy and the factors supporting the growing popularity of T-cell based therapies.

Chapter 4 provides a comprehensive overview of the current landscape of the T-cell immunotherapy market. It features information on various types of therapies that are currently in different stages of development (clinical and preclinical / discovery). It includes a detailed analysis of the T-cell immunotherapy pipeline, specifically, providing information on the most commonly targeted disease indications, current phases of development of individual therapies, specific molecular targets, type of developer(s) and the key companies involved in the development of different types of T-cell therapies, namely CAR-T, TCR and TIL.

Chapter 5 focuses on CAR-T cell based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. It discusses the molecular targets that are currently under investigation, the current challenges in this domain, such as toxicity issues, and other relevant parameters. To offer due credit to the work of eminent researchers in this domain, we have mapped the locations of key opinion leaders across the globe. This section also includes detailed profiles of the late stage therapies that are under development. Each profile features a general overview of the therapy and provides information on additional aspects, such as the history of development, clinical trial timeline, clinical trial results, manufacturing information, estimated cost of treatment and details on the treatment regimen itself.

Chapter 6 focuses on TCR cell based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. It discusses the molecular targets that are currently under investigation, the current challenges in this domain, such as toxicity issues, and other relevant parameters. To offer due credit to the work of eminent researchers in this domain, we have mapped the locations of key opinion leaders across the globe. This section also includes detailed profiles of the late stage therapies that are under development. Each profile features a general overview of the therapy and provides information on additional aspects, such as the history of development, clinical trial timeline, clinical trial results, manufacturing information, estimated cost of treatment and details on the treatment regimen itself.

Chapter 7 elaborates on the TIL based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. To offer due credit to the work of eminent researchers in this domain, we have mapped the locations of key opinion leaders across the globe. This section also includes detailed profiles of the late stage therapies that are under development. Each profile features a general overview of the therapy and provides information on additional aspects, such as the history of development, clinical trial timeline, clinical trial results, manufacturing information, estimated cost of treatment and details on the treatment regimen itself.

Chapter 8 features an elaborate discussion on the future opportunity presented by T-cell therapies. It provides a comprehensive market forecast analysis for molecules that are in the advanced stages of development (phase I/II, phase II and phase II/III), taking into consideration the target patient population, existing competition, likely adoption rates and the likely price of T-cell therapies.

Chapter 9 provides an analysis of the various T-cell therapies that are being developed for the treatment of commonly targeted indications, including hematological cancers and solid tumors. It is worth mentioning that the aforementioned types of oncological indications have been the prime focus of companies developing T-cell immunotherapies. The section also highlights key epidemiological facts and the currently available treatment solutions for each indication.

Chapter 10 focuses on emerging technological platforms that mediate/assist the growth of the T-cell market. It includes detailed discussions on various novel and innovative technologies, along with brief information about key technology providers.

Chapter 11 provides an overview of the emerging trends related to T-cell immunotherapy on social media. It includes data representing the popularity of T-cell products on Twitter over the last five years.

Chapter 12 presents a detailed analysis on the partnerships and agreements established between various players concerning T-cell immunotherapies in the past few years. The section also highlights the financial details of the agreements (wherever available). The partnership activity in this domain has been analyzed on the basis of the year of establishment of the company, the type of partnership model employed, the companies involved, therapy type and prominent product candidates involved.

Chapter 13 provides details on the various investments and grants awarded to players focused on the development of T-cell immunotherapies. The analysis highlights the growing interest of the VC community and other strategic investors in this domain.

Chapter 14 offers details of other novel T-cell based technologies, apart from CAR-Ts, TCRs and TILs, which are currently being investigated. We have provided a brief overview of these upcoming therapies, along with details of their mechanisms of action and the process followed for dose administration.

Chapter 15 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities.For these players, we have included details, such as the scale of operation, compliance to cGMP standards, location of various manufacturing facilities and the products being manufactured.

Chapter 16 highlights our view point on the various factors that must be considered while pricing the cell based therapies. It features discussions on different models / approaches that a pharmaceutical company can follow to decide the price at which their T-cell based immunotherapy product is likely to be marketed.

Chapter 17 includes detailed company profiles of the leading players in the T-cell immunotherapy market. Each company profile includes information such as financial performance, geographical presence, T-cell immunotherapy pipeline, collaborations and recent developments. Additionally, we have also provided details of the strategic / venture capital investments made in these companies.

Chapter 18 is a collection of transcripts of interviews conducted during the course of this study. In this chapter, we have presented the details of our conversations with Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Peter Ho (Director, Process Development, Lion Biotechnologies), AinoKalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma) and Miguel Forte (Chief Operating Officer, TxCell).

Chapter 19 summarizes the entire report. Here, we have provided a list of key takeaways and our independent opinion on the current state and future opportunity in this field.

Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 21 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.

Table of Contents

1. Preface

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. Executive Summary

3. Introduction

  • 3.1. Chapter Overview
  • 3.2. The Four Pillars of Cancer Therapy
  • 3.3. Immunotherapy: Gaining a Strong Foothold
  • 3.4. Immuno-Oncology: Fundamentals of Cancer Immunotherapy
  • 3.5. Classification of Cancer Immunotherapies
    • 3.5.1. By Mechanism of Action
    • 3.5.2. By Type of Target
    • 3.5.3. By Approach
    • 3.5.4. By Product Class
      • 3.5.4.1. Monoclonal Antibodies
      • 3.5.4.2. Bispecific Antibodies
      • 3.5.4.3. Cytokines
      • 3.5.4.4. Cell Based Therapies
  • 3.6. T-Cell Immunotherapy: Historical Evolution
  • 3.7. T-Cell Immunotherapy: Key Considerations
  • 3.8. Strategies Employed for Redirection of T-Cells
  • 3.9. T-Cell Transduction / Transfection Methods
    • 3.9.1. Retroviral Vectors
    • 3.9.2. Lentiviral Vectors
    • 3.9.3. Non-viral Transfection Methods
    • 3.9.3.1. Sleeping Beauty Transposon
  • 3.10. T-Cell Immunotherapy: Targeted Therapeutic Areas
  • 3.11. T-Cell Immunotherapy: Key Challenges

4. Market Landscape

  • 4.1. Chapter Overview
  • 4.2. T-Cell Immunotherapy: An Evolving Landscape
  • 4.3. T-Cell Immunotherapy: A Promising Pipeline
    • 4.3.1. T-Cell Immunotherapy: CAR-T Cells
      • 4.3.1.1. Clinical Pipeline
      • 4.3.1.2. Preclinical / Discovery Pipeline
    • 4.3.2. T-Cell Immunotherapy: TCR Cells
      • 4.3.2.1. Clinical Pipeline
      • 4.3.2.2. Preclinical / Discovery Pipeline
    • 4.3.3. T-Cell Immunotherapy: TIL Cells
      • 4.3.3.1. Clinical Pipeline
      • 4.3.3.2. Preclinical / Discovery Pipeline
  • 4.4. T-Cell Immunotherapy: Distribution of Candidate Therapies by Type of Product
  • 4.5. T-Cell Immunotherapy: Distribution of Candidate Therapies by Type of Developer
  • 4.6. T-Cell Immunotherapy: Distribution of Candidate Therapies by Phase of Development
  • 4.7. T-Cell Immunotherapy: Target Oncological Indications
    • 4.7.1. CAR-T Cell Immunotherapy: Popular Target Indications
    • 4.7.2. TCR Cell Immunotherapy: Popular Target Indications
    • 4.7.3. TIL Cell Immunotherapy: Popular Target Indications
  • 4.8. T-Cell Immunotherapy: Key Industry Players
  • 4.9. T-Cell Immunotherapy: Key Non-Industry Players
  • 4.10. T-Cell Immunotherapy: Most Popular Targets for CAR-T and TCR Therapies

5. Chimeric Antigen Receptor-T (CAR-T) Cell Therapy

  • 5.1. Introduction
  • 5.2. History of Development
  • 5.3. Key Opinion Leaders
  • 5.4. Anatomical Layout of Chimeric Antigen Receptor
  • 5.5. Development of Chimeric Antigen Receptors
  • 5.6. Development of CAR-T Cells
  • 5.7. Universal CAR-Ts
  • 5.8. Route of Administration
  • 5.9. Toxicity Issues
    • 5.9.1. Cytokine Release Syndrome (CRS)
    • 5.9.2. On-Target Off-Tumor Toxicity
    • 5.9.3. Encephalopathy and B-Cell Aplasia
  • 5.10. Management of Toxicity Issues
    • 5.10.1. Target Selection
    • 5.10.2. Cell Persistence
    • 5.10.3. Receptor Expression
  • 5.11. CD19: An Attractive Target
  • 5.12. Other Targets
  • 5.13. Challenges Associated with CAR-T Therapy
    • 5.13.1. Competitive Risks
    • 5.13.2. Clinical Risks
    • 5.13.3. Regulatory Risks
    • 5.13.4. Commercial Risks
  • 5.14. CTL019 (Novartis)
    • 5.14.1. Introduction
    • 5.14.2. History of Development
    • 5.14.3. Development Status
    • 5.14.4. Key Clinical Trial Results
      • 5.14.4.1. Acute Lymphoblastic Leukemia
      • 5.14.4.2. Non-Hodgkin's Lymphoma
      • 5.14.4.3. Chronic Lymphocytic Leukemia
      • 5.14.4.4. Multiple Myeloma
    • 5.14.5. Dosage Regimen, Treatment Cost and Manufacturing
  • 5.15. JCAR (Juno Therapeutics)
    • 5.15.1. Introduction
    • 5.15.2. CAR-T Design
    • 5.15.3. Development Status
    • 5.15.4. Key Clinical Trial Results
      • 5.15.4.1. JCAR014
      • 5.15.4.2. JCAR015
      • 5.15.4.3. JCAR017
      • 5.15.4.4. JCAR018
    • 5.15.5. Dosage Regimen and Manufacturing
  • 5.16. KTE-C19 (Kite Pharma)
    • 5.16.1. Introduction
    • 5.16.2. Development Status
    • 5.16.3. Key Clinical Trial Results
      • 5.16.3.1. Non-Hodgkin's Lymphoma
      • 5.16.3.2. Acute Lymphoblastic Leukemia
    • 5.16.4. Dosage Regimen and Manufacturing
    • 5.16.5. Next Generation eACT CAR Candidates
  • 5.17. CAR-T Series (Cellular Biomedicine Group)
    • 5.17.1. Introduction
    • 5.17.2. History of Development
    • 5.17.3. Development Status
    • 5.17.4. Key Clinical Trial Results
      • 5.17.4.1. CBM-EGFR.1
      • 5.17.4.2. CBM-C19.1
      • 5.17.4.3. CBM-C20.1
      • 5.17.4.4. CBM-C30.1
    • 5.17.5. Dosage Regimen, Manufacturing and Patent Portfolio
  • 5.18. CD19 CAR (Takara Bio)
    • 5.18.1. Introduction
    • 5.18.2. Development Status
    • 5.18.3. Key Clinical Trial Results
    • 5.18.4. Dosage Regimen and Manufacturing

6. T-Cell Receptor (TCR) Based Therapies

  • 6.1. Introduction
  • 6.2. Structure of the T-Cell Receptor
  • 6.3. Difference between CAR and TCR
  • 6.4. History of Development
  • 6.5. Key Opinion Leaders
  • 6.6. Mechanism of Action
  • 6.7. Safety Issues
    • 6.7.1. Insertional Mutagenesis
    • 6.7.2. On-Target Off-Tumor Toxicity and Cross-Reactivity
    • 6.7.3. TCR Mismatch Pairing
  • 6.8. Prerequisites of Antigen-Specific T-Cell Receptors
  • 6.9. Identifying Strategies that Enhance Antitumor Efficacy
    • 6.9.1. Affinity Enhanced TCRs
    • 6.9.2. Soluble TCR Based Biologics
  • 6.10. SPEAR T-Cells (Adaptimmune)
    • 6.10.1. Introduction
      • 6.10.1.1. NY-ESO SPEAR T-Cell
      • 6.10.1.2. Mage-A10 T-Cell Therapy
      • 6.10.1.3. AFP T-Cell therapy
    • 6.10.2. History of Development
    • 6.10.3. SPEAR T-cells Technology Platform
    • 6.10.4. Development Status
    • 6.10.5. Key Clinical Trial Results
      • 6.10.5.1. Multiple Myeloma
      • 6.10.5.2. Synovial Sarcoma
      • 6.10.5.3. Ovarian Cancer
      • 6.10.5.4. Multiple Myeloma, Synovial Sarcoma and Ovarian Cancer: Combined Results
    • 6.10.6. Dosage Regimen and Manufacturing Information
  • 6.11. ALT-801 (AltorBioScience)
    • 6.11.1. Introduction
    • 6.11.2. History of Development
    • 6.11.3. Development Status
    • 6.11.4. Key Clinical Trial Results
      • 6.11.4.1. Urothelial Carcinoma
      • 6.11.4.2. Bladder Cancer
    • 6.11.5. Dosage Regimen and Patent Portfolio
  • 6.12. IMCgp100 (Immunocore)
    • 6.12.1. Introduction
    • 6.12.2. Development Status
    • 6.12.3. Key Clinical Trial Results
    • 6.12.4. Dosage Regimen
  • 6.13. JTCR016 (Juno Therapeutics)
    • 6.13.1. Introduction
    • 6.13.2. Development Status
    • 6.13.3. Key Clinical Trial Results
    • 6.13.4. Dosage Regimen
  • 6.14. WT1 TCR Gene Therapy (Cell and Gene Therapy Catapult)
    • 6.14.1. Introduction
    • 6.14.2. History of Development
    • 6.14.3. Development Status
    • 6.14.4. Key Clinical Trial Results
    • 6.14.5. Dosage Regimen and Manufacturing

7. Tumor Infiltrating Lymphocytes (TIL) Based Therapies

  • 7.1. Introduction
  • 7.2. History of Development
  • 7.3. Key Opinion Leaders
  • 7.4. Research Strategies to Enhance Efficacy
  • 7.5. A Prognostic Tool
  • 7.6. Manufacturing Process
  • 7.7. LN-144 (Lion Biotechnologies)
    • 7.7.1. Introduction
    • 7.7.2. Development Status
    • 7.7.3. Key Clinical Trial Results
    • 7.7.4. Dosage Regimen and Manufacturing
    • 7.7.5. Patent Portfolio
    • 7.7.6. Next-Generation TILs
  • 7.8. TIL (Nantes University Hospital)
    • 7.8.1. Introduction
    • 7.8.2. Development Status
    • 7.8.3. Key Experimental Results
    • 7.8.4. Dosage Regimen and Manufacturing
  • 7.9. TIL (Netherlands Cancer Institute)
    • 7.9.1. Introduction
    • 7.9.2. Development Status
    • 7.9.3. Key Clinical Trial Results
    • 7.9.4. Dosage Regimen and Manufacturing

8. Market Opportunity

  • 8.1. Chapter Overview
  • 8.2. Scope and Limitations
  • 8.3. Forecast Methodology
  • 8.4. Overall T-Cell Immunotherapy Market(Till 2030)
  • 8.5. Overall Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Market
    • 8.5.1. CTL019 (Novartis)
      • 8.5.1.1. Target Population
      • 8.5.1.2. Sales Forecast(Till 2030)
    • 8.5.2. KTE-C19 (Kite Pharma)
      • 8.5.2.1. Target Population
      • 8.5.2.2. Sales Forecast (Till 2030)
    • 8.5.3. JCAR015 (Juno Therapeutics)
      • 8.5.3.1. Target Population
        • 8.5.3.1.1. Sales Forecast(Till 2030)
    • 8.5.4. CBM-CD30 CAR-T (Cellular Biomedicine Group)
      • 8.5.4.1. Target Population
      • 8.5.4.2. Sales Forecast (Till 2030)
    • 8.5.5. CBM-CD20 CAR-T (Cellular Biomedicine Group)
      • 8.5.5.1. Target Population
      • 8.5.5.2. Sales Forecast(Till 2030)
    • 8.5.6. CBM-EGFR.1 CAR-T (Cellular Biomedicine Group)
      • 8.5.6.1. Target Population
      • 8.5.6.2. Sales Forecast (Till 2030)
    • 8.5.7. CD 19 CAR-T (Sinobioway Cell Therapy)
      • 8.5.7.1. Target Population
      • 8.5.7.2. Sales Forecast (Till 2030)
    • 8.5.8. CD 19 CAR-T (Takara Bio)
      • 8.5.8.1. Target Population
      • 8.5.8.2. Sales Forecast (Till 2030)
    • 8.5.9. GPC3 CAR-T (Shanghai Genechem)
      • 8.5.9.1. Target Population
      • 8.5.9.2. Sales Forecast (Till 2030)
    • 8.5.10. JCAR017 (Juno Therapeutics)
      • 8.5.10.1. Target Population
      • 8.5.10.2. Sales Forecast (Till 2030)
  • 8.6. Overall TCR Market (Till 2030)
    • 8.6.1. IMCgp100 (Immunocore)
      • 8.6.1.1. Target Population
      • 8.6.1.2. Sales Forecast(Till 2030)
    • 8.6.2. HPV-16E6-TCR (Kite Pharma)
      • 8.6.2.1. Target Population
      • 8.6.2.2. Sales Forecast (Till 2030)
    • 8.6.3. NY-ESO-1 TCR (Adaptimmune)
      • 8.6.3.1. Target Population
      • 8.6.3.2. Sales Forecast(Till 2030)
    • 8.6.4. HBV antigen specific TCR redirected T-Cell (Lion TCR)
      • 8.6.4.1. Target Population
      • 8.6.4.2. Sales Forecast(Till 2030)
    • 8.6.5. ALT-801 (AltorBioScience)
      • 8.6.5.1. Target Population
      • 8.6.5.2. Sales Forecast(Till 2030)
    • 8.6.6. JTCR016 (Juno Therapeutics)
      • 8.6.6.1. Target Population
      • 8.6.6.2. Sales Forecast (Till 2030)
    • 8.6.7. KITE-718 (MAGE A3/A6) (Kite Pharma)
      • 8.6.7.1. Target Population
      • 8.6.7.2. Sales Forecast (Till 2030)
    • 8.6.8. MAGE A3 (Kite Pharma)
      • 8.6.8.1. Target Population
      • 8.6.8.2. Sales Forecast (Till 2030)
    • 8.6.9. WT-1 TCR (Cell Therapy Catapult)
      • 8.6.9.1. Target Population
      • 8.6.9.2. Sales Forecast(Till 2030)
    • 8.6.10. MAGE A-10 TCR (Adaptimmune)
      • 8.6.10.1. Target Population
      • 8.6.10.2. Sales Forecast(Till 2030)
  • 8.7. Overall TIL Therapy Market (Till 2030)
    • 8.7.1. LN-144 (Lion Biotechnologies)
      • 8.7.1.1. Target Population
      • 8.7.1.2. Sales Forecast (Till 2030)
    • 8.7.2. TIL Therapy (Nantes University)
      • 8.7.2.1. Target Population
      • 8.7.2.2. Sales Forecast (Till 2030)
    • 8.7.3. TIL Therapy (Netherlands Cancer Institute)
      • 8.7.3.1. Target Population
      • 8.7.3.2. Sales Forecast (Till 2030)

9. Key Therapeutic Areas for T-Cell Therapies

  • 9.1. Chapter Overview
  • 9.2. Introduction
  • 9.3. Hematological Malignancies
    • 9.3.1. Leukemia and Lymphoma
      • 9.3.1.1. Leukemia: Introduction and Epidemiology
        • 9.3.1.1.1. Acute Myeloid Leukemia (AML)
        • 9.3.1.1.2. Chronic Myeloid Leukemia (CML)
        • 9.3.1.1.3. Acute Lymphocytic Leukemia (ALL)
        • 9.3.1.1.4. Chronic Lymphocytic Leukemia (CLL)
      • 9.3.1.2. Lymphoma: Introduction and Epidemiology
      • 9.3.1.3. Current Treatment Landscape
        • 9.3.1.3.1. Targeted Therapies
      • 9.3.1.4. T-Cell Immunotherapy and Research Landscape
        • 9.3.1.4.1. CAR-Ts and Leukemia / Lymphoma
        • 9.3.1.4.2. TCRs and Leukemia / Lymphoma
    • 9.3.2. Multiple Myeloma
      • 9.3.2.1. Introduction and Epidemiology
      • 9.3.2.2. Current Treatment Landscape
      • 9.3.2.3. T-Cell Immunotherapy and Research Landscape
  • 9.4. Solid Tumors
    • 9.4.1. Metastatic Melanoma
      • 9.4.1.1. Introduction and Epidemiology
      • 9.4.1.2. Current Treatment Landscape
      • 9.4.1.3. T-Cell Immunotherapy and Research Landscape
        • 9.4.1.3.1. TILs and Metastatic Melanoma
          • 9.4.1.3.1.1. TIL Research at the MD Anderson Cancer Center, US
          • 9.4.1.3.1.2. TIL Research at the Sheba Medical Centre, Israel
        • 9.4.1.3.2. TCRs and Metastatic Melanoma
        • 9.4.1.3.3. CAR-Ts and Metastatic Melanoma
    • 9.4.2. Lung Cancer
      • 9.4.2.1. Introduction and Epidemiology
      • 9.4.2.2. Current Treatment Landscape
      • 9.4.2.3. T-Cell Immunotherapy and Research Landscape
    • 9.4.3. Bladder Cancer
      • 9.4.3.1. Introduction and Epidemiology
      • 9.4.3.2. Current Treatment Landscape
      • 9.4.3.3. T-Cell Immunotherapy and Research Landscape
    • 9.4.4. Kidney Cancer
      • 9.4.4.1. Introduction and Epidemiology
      • 9.4.4.2. Current Treatment Landscape
      • 9.4.4.3. T-Cell Immunotherapy and Research Landscape
    • 9.4.5. Ovarian Cancer
      • 9.4.5.1. Introduction and Epidemiology
      • 9.4.5.2. Current Treatment Landscape
      • 9.4.5.3. T-Cell Immunotherapy and Research Landscape
        • 9.4.5.3.1. CAR-Ts and Ovarian Cancer
    • 9.4.6. Breast Cancer
      • 9.4.6.1. Introduction and Epidemiology
      • 9.4.6.2. Current Treatment Landscape
      • 9.4.6.3. T-Cell Immunotherapy and Research Landscape
        • 9.4.6.3.1. CAR-Ts and Breast Cancer
        • 9.4.6.3.2. TILs and Breast Cancer

10. Emerging Technologies

  • 10.1. Chapter Overview
  • 10.2. Introduction
  • 10.3. Genome Editing Technologies: Introduction
  • 10.4. Genome Editing Technologies: Applications
    • 10.4.1. Genome Editing Technologies: Emerging Technology Platforms Used in T-Cell Therapies
      • 10.4.1.1. CRISPR/Cas9 System
        • 10.4.1.1.1. Key Components and Function
        • 10.4.1.1.2. Mechanism of Action
        • 10.4.1.1.3. Targeting Efficiency and Challenges
        • 10.4.1.1.4. Next-GEN CRISPR Technology
        • 10.4.1.1.5. Technology Providers
          • 10.4.1.1.5.1. Editas Medicine
          • 10.4.1.1.5.2. Intellia Therapeutics
          • 10.4.1.1.5.3. CRISPR Therapeutics
      • 10.4.1.2. TALENs
        • 10.4.1.2.1. Structural Features
        • 10.4.1.2.2. Mechanism of Action
        • 10.4.1.2.3. Advantages and Challenges
        • 10.4.1.2.4. Technology Providers
          • 10.4.1.2.4.1. Cellectis
          • 10.4.1.2.4.2. Editas Medicine
      • 10.4.1.3. megaTAL
        • 10.4.1.3.1. Technology Providers
          • 10.4.1.3.1.1. bluebird bio
        • 10.4.1.4. Zinc Finger Nuclease
          • 10.4.1.4.1. Technology Providers
            • 10.4.1.4.1.1. Sangamo Biosciences
  • 10.5. Designing T-Cell Therapies with Improved Characteristics
    • 10.5.1. Technology for Targeting Multiple Cancers
      • 10.5.1.1. Antibody Coupled T-Cell Receptor, Unum Therapeutics
      • 10.5.1.2. NKR-T Platform, Celyad
    • 10.5.2. Technology For Improved Safety
      • 10.5.2.1. Armored CAR, Juno Therapeutics
      • 10.5.2.2. RheoSwitch Therapeutic System, Intrexon
      • 10.5.2.3. Inducible Caspase 9 Safety Switch, BellicumPharmaceuticals
        • 10.5.2.3.1. CaspaCIDe Technology
        • 10.5.2.3.2. CIDeCAR Technology
        • 10.5.2.3.3. GoCAR-T Technology
      • 10.5.2.4. On-Off Switch, Multiple Companies
        • 10.5.2.4.1. Inhibitory CAR (iCAR), Juno Therapeutics
        • 10.5.2.4.2. On-Off Switch, Theravectys
      • 10.5.2.5. Allogeneic Technology
        • 10.5.2.5.1. CIK CAR-T Cells, Formula Pharmaceuticals
        • 10.5.2.5.2. Allogeneic Platform, Celyad
        • 10.5.2.5.3. Allogeneic Platform, Cellectis

11. Social Media: Emerging Trends

  • 11.1. Chapter Overview
  • 11.2. Trends on Twitter
    • 11.2.1. Yearly Trends on Twitter
    • 11.2.2. Popular Keywords on Twitter
    • 11.2.3. Most Popular Drugson Twitter

12. Partnerships and Collaborations

  • 12.1. Chapter Overview
  • 12.2. Partnership Models
  • 12.3. Recent Collaborations
    • 12.3.1. Distribution of Partnerships by Year
    • 12.3.2. Distribution of Partnerships by Type of Model
    • 12.3.3. Leading Industry Collaborators
    • 12.3.4. Leading Non-Industry Collaborators
    • 12.3.5. Distribution of Partnerships by Type of Therapy
    • 12.3.6. Distribution of Partnerships by Product Therapy

13. Venture Capital Support

  • 13.1. Chapter Overview
  • 13.2. T-Cell Immunotherapy: List of Funding Instances
    • 13.2.1. T-Cell Immunotherapy: Funding Instances, Cumulative Number of Funding Instances by Year, pre-2009-2016
    • 13.2.2. T-Cell Immunotherapy: Funding Instances, Cumulative Distribution of Amount Invested by Year, pre-2009-2016
    • 13.2.3. T-Cell Immunotherapy: Funding Instances, Distribution of Instances by Type of Funding
    • 13.2.4. T-Cell Immunotherapy: Funding Instances, Distribution of Amount Invested by Type of Funding

14. Other T-Cell Immunotherapies

  • 14.1. Chapter Overview
  • 14.2. Other T-Cell Immunotherapies
    • 14.2.1. Treg Cell Therapy
      • 14.2.1.1. Caladrius Biosciences
      • 14.2.1.2. TxCell
      • 14.2.1.3. TRACT Therapeutics
      • 14.2.1.4. Other Companies
    • 14.2.2. T-Cell Based Vaccines
      • 14.2.2.1. Immunovative Therapies
      • 14.2.2.2. Opexa Therapeutics
      • 14.2.2.3. TVAX
    • 14.2.3. Virus-Driven T-Cell Therapies
      • 14.2.3.1. Atara Biotherapeutics
      • 14.2.3.2. Cell Medica
      • 14.2.3.3. Tessa Therapeutics
    • 14.2.4. Fucosylation Technology Platform
      • 14.2.4.1. Targazyme
    • 14.2.5. PD-1 Knockout Engineered T-Cells
      • 14.2.5.1. Chengdu MedGenCell
    • 14.2.6. TAC-T Cells
      • 14.2.6.1. Triumvira
    • 14.2.7. Vγ9δ2 T cell T-Cell immunotherapy
      • 14.2.7.1. GammaCell Biotechnologies

15. Case Study: Cell Therapy Manufacturing

  • 15.1. Chapter Overview
  • 15.2. Introduction
  • 15.3. Key Challenges
  • 15.4. Current Trends
    • 15.4.1. Companies with In-house Capabilities
    • 15.4.2. Contract Manufacturers
  • 15.5. Key Considerations for a Manufacturing Site
  • 15.6. Regulatory Landscape

16. T-Cell Immunotherapy: Cost Price Analysis

  • 16.1. Chapter Overview
  • 16.2. Cell / Gene Therapies: Factors Contributing Towards Higher Price Tags
  • 16.3. T-Cell Immunotherapy: Pricing Models
    • 16.3.1. Pricing Model: Based On Associated Costs
    • 16.3.2. Pricing Model: Based On Competition
    • 16.3.3. Pricing Model: Based on Expert Opinions

17. Company Profiles

  • 17.1. Chapter Overview
  • 17.2. Adaptimmune
    • 17.2.1. Company Overview
    • 17.2.2. Financial Information
    • 17.2.3. Product Portfolio
    • 17.2.4. Manufacturing Capabilities
    • 17.2.5. Collaborations
      • 17.2.5.1. Immunocore
      • 17.2.5.2. Progenitor Cell Therapy
      • 17.2.5.3. Thermo Fisher Scientific
      • 17.2.5.4. GlaxoSmithKline
      • 17.2.5.5. Universal Cells
      • 17.2.5.6. MD Anderson Cancer Center
      • 17.2.5.7. Merck
      • 17.2.5.8. Bellicum Pharmaceuticals
    • 17.2.6. Future Outlook
  • 17.3. AltorBioScience
    • 17.3.1. Company Overview
    • 17.3.2. Financial Performance
    • 17.3.3. Product Portfolio
    • 17.3.4. Patent Portfolio
    • 17.3.5. Collaborations
      • 17.3.5.1. Massachusetts General Hospital and Howard Hughes Medical Institute
      • 17.3.5.2. National Cancer Institute (NCI)
      • 17.3.5.3. NantKwest
    • 17.3.6. Future Outlook
  • 17.4. bluebird Bio
    • 17.4.1. Company Overview
    • 17.4.2. Financial Performance
    • 17.4.3. Product Portfolio
    • 17.4.4. Collaborations
      • 17.4.4.1. Celgene Corporation
      • 17.4.4.2. Baylor College of Medicine
      • 17.4.4.3. Pregenen
      • 17.4.4.4. Five Prime Therapeutics
      • 17.4.4.5. Kite Pharma
      • 17.4.4.6. ViroMed
    • 17.4.5. Future Outlook
  • 17.5. Cellectis
    • 17.5.1. Company Overview
    • 17.5.2. Financial Information
    • 17.5.3. Product Portfolio
    • 17.5.4. Collaborations
      • 17.5.4.1. Servier
      • 17.5.4.2. CELLforCURE
      • 17.5.4.3. Pfizer
      • 17.5.4.4. Oncodesign
      • 17.5.4.5. Ohio University
      • 17.5.4.6. Weill Cornell Medical College
      • 17.5.4.7. The University of Texas MD Anderson Cancer Center
      • 17.5.4.8. Takara Biosciences
      • 17.5.4.9. MabQuest
    • 17.5.5. Future Outlook
  • 17.6. Cellular Biomedicine Group
    • 17.6.1. Company Overview
    • 17.6.2. Financial Information
    • 17.6.3. Product Portfolio
    • 17.6.4. Manufacturing Capabilities
    • 17.6.5. Collaborations
      • 17.6.5.1. Agreen Biotech
      • 17.6.5.2 Chinese PLA General Hospital
    • 17.6.6. Future Outlook
  • 17.7. Immunocore
    • 17.7.1. Company Overview
    • 17.7.2. Financial Information
    • 17.7.3. Product Portfolio
    • 17.7.4. Collaborations
      • 17.7.4.1. Cardiff University
      • 17.7.4.2. Genentech
      • 17.7.4.3. GlaxoSmithKline
      • 17.7.4.4. Medimmune
      • 17.7.4.5. Eli Lilly
      • 17.7.4.6. CMC Biologics
    • 17.7.5. Future Outlook
  • 17.8. Juno Therapeutics
    • 17.8.1. Company Overview
    • 17.8.2. Financial Information
    • 17.8.3. Product Portfolio
    • 17.8.4. Litigations
    • 17.8.5. Manufacturing Capabilities
    • 17.8.6. Collaborations
      • 17.8.6.1. Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Center, Seattle Children's Research Institute
      • 17.8.6.2. Opus Bio
      • 17.8.6.3. MedImmune/AstraZeneca
      • 17.8.6.4. Stage Cell Therapeutics
      • 17.8.6.5. Editas Medicine
      • 17.8.6.6. Fate Therapeutics
      • 17.8.6.7. X-Body
      • 17.8.6.8. Celgene
      • 17.8.6.9. AbVitro
      • 17.8.6.10. Wuxi AppTec
      • 17.8.6.11. RedoxTherapies
      • 17.8.6.12. Eureka Therapeutics, Memorial Sloan Kettering Cancer Center
    • 17.8.7. Future Outlook
  • 17.9. Kite Pharma
    • 17.9.1. Company Overview
    • 17.9.2. Financial Information
    • 17.9.3. Product Portfolio
    • 17.9.4. Manufacturing Capabilities
    • 17.9.5. Collaborations
      • 17.9.5.1. National Cancer Institute / National Institutes of Health
      • 17.9.5.2. Cabaret Biotech
      • 17.9.5.3. NeoStem
      • 17.9.5.4. Amgen
      • 17.9.5.5. Tel Aviv Sourasky Medical Center
      • 17.9.5.6. T-Cell Factory (TCF)
      • 17.9.5.7. bluebird bio
      • 17.9.5.8. Leukemia and Lymphoma Society
      • 17.9.5.9. Netherlands Cancer Institute
      • 17.9.5.10. Alpine Immune Sciences
      • 17.9.5.11. GE Global Research
      • 17.9.5.12. Leiden University Medical Center
      • 17.9.5.13. Genentech
      • 17.9.5.14. Cell Designs Labs
      • 17.9.5.15. University of California
      • 17.9.5.16. BioLife Solutions
    • 17.9.6. Future Outlook
  • 17.10. Lion Biotechnologies
    • 17.10.1. Company Overview
    • 17.10.2. Financial Information
    • 17.10.3. Product Portfolio
    • 17.10.4. Manufacturing Capabilities
    • 17.10.5. Collaborations
      • 17.10.5.1. Lonza
      • 17.10.5.2. H. Lee Moffitt Cancer Center and Research Institute
      • 17.10.5.3. National Cancer Institute
      • 17.10.5.4. National Institutes of Health
      • 17.10.5.5. WuXiAppTec
      • 17.10.5.6. MedImmune
      • 17.10.5.7. PolyBioCept
      • 17.10.5.8. Karolinska University Hospital
    • 17.10.6. Upcoming Products: Next Generation TILs
    • 17.10.7. Future Outlook
  • 17.11. Novartis
    • 17.11.1. Company Overview
    • 17.11.2. Financial Information
    • 17.11.3. Product Portfolio
    • 17.11.4. Patent Litigation
    • 17.11.5. Manufacturing Capabilities
    • 17.11.6. Collaborations
      • 17.11.6.1. University of Pennsylvania
      • 17.11.6.2. Oxford BioMedica
      • 17.11.6.3. Intellia Therapeutics and Caribou Biosciences
    • 17.11.7. Future Outlook
  • 17.12. Takara Bio
    • 17.12.1. Company Overview
    • 17.12.2. Financial Information
    • 17.12.3. Product Portfolio
    • 17.12.4. Manufacturing Capabilities
    • 17.12.5. Collaborations
      • 17.12.5.1. Tianjin Medical University, Cancer Institute and Hospital
      • 17.12.5.2. Memorial Sloan Kettering Cancer Center
      • 17.12.5.3. Jichi Medical University Hospital
      • 17.12.5.4. Cellectis
      • 17.12.5.5. Mile University School of Medicines
    • 17.12.6. Future Outlook
  • 17.13. Unum Therapeutics
    • 17.13.1. Company Overview
    • 17.13.2. Financial Information
    • 17.13.3. Product Portfolio
    • 17.13.4. Collaborations
      • 17.13.4.1. Seattle Genetics
    • 17.13.5. Future Outlook

18. Interview Transcripts

  • 18.1. Chapter Overview
  • 18.2. Vincent Brichard, Vice President, Immuno-Oncology, Celyad
  • 18.3. Peter Ho, Director, Process Development, Lion Biotechnologies
  • 18.4. AinoKalervo, Competitive Intelligence Manager, Strategy & Business Development, Theravectys
  • 18.5. Adrian Bot, Vice President, Translational Sciences, Kite Pharma
  • 18.6. Miguel Forte, Chief Operating Officer, TxCell

19. Conclusion

  • 19.1. T-Cell Therapies Have Emerged as a Promising Segment of the Immunotherapy Market
  • 19.2. Development Activity in the Domain is Led by Academic Institutes, Some of Which Have Collaborated with Industry Players
  • 19.3. Hematological Malignancies and Solid Tumors are Currently the Major Target Indications
  • 19.4. A Number of Novel Technological Platforms Have Emerged as Vital Enablers of Growth In This Market
  • 19.5. A Significant Number of Strategic Alliances Have Been Forged in Order To Advance the Development of Different Product Candidates
  • 19.6. Manufacturing Complexities and High Development Cost of These Therapies Necessitate Premium Pricing
  • 19.7. Multiple Novel Types of Immunotherapies, Other Than CAR-T, TCR and TIL, are Expected to Emerge in The Mid-Long Run
  • 19.8. Backed by a Progressive Pipeline and VC Support, the Market is Poised for Significant Growth

20. Appendix 1: Tabulated Data

21. Appendix 2: List of Companies and Organizations

List of Figures

  • Figure 3.1 The Four Pillars of Cancer Therapy
  • Figure 3.2 Difference between Active and Passive Immunotherapies
  • Figure 3.3 Difference between Specific and Non-Specific Immunotherapies
  • Figure 3.4 3Es of the Immune System
  • Figure 3.5 Strategies Employed for the Redirection of T-Cells
  • Figure 3.6 T-Cell Immunotherapy: Target Therapeutic Areas
  • Figure 3.7 T-Cell Immunotherapy: Key Challenges
  • Figure 4.1 T-Cell Immunotherapy Pipeline: Distribution by Type of Product
  • Figure 4.2 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer
  • Figure 4.3 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer across CAR-Ts, TCRs and TILs
  • Figure 4.4 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development
  • Figure 4.5 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development across CAR-T, TCR and TIL
  • Figure 4.6 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area
  • Figure 4.7 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area across CAR-Ts, TCRs and TILs
  • Figure 4.8 T-Cell Immunotherapy Pipeline: Popular Target Indications
  • Figure 4.9 CAR-T Cell Immunotherapy: Popular Target Indications
  • Figure 4.10 TCR Cell Immunotherapy: Popular Target Indications
  • Figure 4.11 TIL Cell Immunotherapy: Popular Target Indications
  • Figure 4.12 T-Cell Immunotherapy Pipeline: Active Industry Players in Clinical Development
  • Figure 4.13 T-Cell Immunotherapy Pipeline: Active Industry Players in Preclinical Development
  • Figure 4.14 T-Cell Immunotherapy Pipeline: Active Non-Industry Players
  • Figure 4.15 CAR-T Cell Therapy Pipeline: Distribution by Target Antigen
  • Figure 4.16 TCR Therapy Pipeline: Distribution by Target Antigen
  • Figure 5.1 Historical Timeline: Development of CAR-T cells
  • Figure 5.2 CAR-T Cell Therapy: Geographical Distribution of Key Opinion Leaders
  • Figure 5.3 CAR-T: Structure and Domains
  • Figure 5.4 CAR-T: CAR Generations Layout
  • Figure 5.5 Development of CAR-T Cells
  • Figure 5.6 Challenges Associated with CAR-T Therapy
  • Figure 5.7 CTL019: Industry Sponsored Clinical Trial Design
  • Figure 5.8 CTL019: Non-Industry Sponsored Clinical Trial Design
  • Figure 5.9 JCAR Series: Industry Sponsored Clinical Trial Design
  • Figure 5.10 JCAR Series: Non-Industry Sponsored Clinical Trial Design
  • Figure 5.11 KTE-C19: Clinical Trial Design
  • Figure 5.12 Manufacturing of CD19 CAR-T Cells: Process Comparison
  • Figure 5.13 Cellular Biomedicine's CAR-T Series: Clinical Trial Design
  • Figure 5.14 Takara Bio's CD19 CAR-T: Clinical Trial Design
  • Figure 6.1 TCR Cell Therapy: Geographical Distribution of Key Opinion Leaders
  • Figure 6.2 TCR Cell Therapy: Development Process
  • Figure 6.3 NY-ESO TCR: Industry Sponsored Clinical Trial Design
  • Figure 6.4 MAGE A-10 TCR: Industry Sponsored Clinical Trial Design
  • Figure 6.5 ALT-801: Clinical Trial Design
  • Figure 6.6 IMCgp100: Clinical Trial Design
  • Figure 6.7 JTCR016: Clinical Trial Design
  • Figure 6.8 WT1 TCR: Clinical Trial Design
  • Figure 7.1 TIL Cell Therapy: Geographical Distribution of Key Opinion Leaders
  • Figure 7.2 TIL Cell Therapy: Manufacturing Process
  • Figure 7.3 LN-144: Clinical Trial Design
  • Figure 7.4 Nantes University Hospital's TIL Therapy: Clinical Trial Design
  • Figure 7.5 Nantes University Hospital's TIL Therapy: Production Procedure
  • Figure 7.6 Netherlands Cancer Institute's TIL Therapy: Clinical Trial Design
  • Figure 8.1 Overall T-Cell Immunotherapy Market (Till 2030): Base Scenario (USD Billion)
  • Figure 8.2 T-Cell Therapy Market, 2020, 2025 and 2030: Base Scenario (USD Million)
  • Figure 8.3 Overall CAR-T Market Forecast(Till 2030): Base Scenario (USD Billion)
  • Figure 8.4 CTL019: Current Status by Highest Phase of Development
  • Figure 8.5 CTL019 Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.6 KTE-C19: Current Status by Highest Phase of Development
  • Figure 8.7 KTE-C19 Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.8 JCAR015 Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.9 CBM-CD30 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.10 CBM-CD20 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.11 CBM-EGFR CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.12 Sinobioway Cell Therapy's CD 19 CAR-T: Current Status by Highest Phase of Development
  • Figure 8.13 Sinobioway Cell Therapy's CD 19 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.14 Takara Bio's CD 19 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.15 GPC3 CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 8.16 JCAR017 Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.17 Overall TCR Market Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.18 IMCgp100 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 8.19 HPV-16E6-TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 8.20 NY-ESO-1 TCR: Current Status by Highest Phase of Development
  • Figure 8.21 NY-ESO-1 TCR Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.22 HBV antigen specific TCR Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.23 ALT-801: Current Status by Highest Phase of Development
  • Figure 8.24 ALT-801 Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.25 JTCR016: Current Status by Highest Phase of Development
  • Figure 8.26 JTCR016 Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.27 KITE-718 (MAGE A3/A6) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 8.28 MAGE A3 Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.29 WT-1 TCR: Current Status by Highest Phase of Development
  • Figure 8.30 WT-1 TCR Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.31 MAGE A-10 TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 8.32 Overall TIL Market Forecast (Till 2030): Base Scenario (USD Billion)
  • Figure 8.33 LN-144 Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.34 TIL Therapy (Nantes University) Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 8.35 TIL Therapy (Netherlands Cancer Institute) Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Figure 9.1 Leukemia: Classification
  • Figure 9.2 Leukemia: Global Epidemiological Distribution
  • Figure 9.3 Lymphoma: Global Epidemiological Distribution
  • Figure 9.4 Multiple Myeloma: Global Epidemiological Distribution
  • Figure 9.5 Melanoma: Global Epidemiological Distribution
  • Figure 9.6 Lung Cancer: Classification
  • Figure 9.7 Lung Cancer: Global Epidemiological Distribution
  • Figure 9.8 Bladder Cancer: Global Epidemiological Distribution
  • Figure 9.9 Kidney Cancer: Global Epidemiological Distribution
  • Figure 9.10 Ovarian Cancer: Global Epidemiological Distribution
  • Figure 9.11 Breast Cancer: Global Epidemiological Distribution
  • Figure 10.1 Genome Editing Technologies: Applications
  • Figure 10.2 Genome Editing Technologies: Emerging Technology Platforms Used in T-Cell Platforms
  • Figure 10.3 T-Cell Therapy: Key Technologies to Enhance Features / Characteristics
  • Figure 10.4 Properties of Enhanced T-Cell Platform
  • Figure 10.5 Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
  • Figure 11.1 T-Cell Immunotherapy Social Media Analysis: Twitter Trends, January 2011-June2016
  • Figure 11.2 T-Cell Immunotherapy Social Media Analysis: Highlights on Twitter, January 2011 - June 2016
  • Figure 11.3 T-Cell Immunotherapy Social Media Analysis: Twitter, Most Popular Candidates, January 2011-June 2016
  • Figure 12.1 T-Cell Immunotherapy: Cumulative Distribution of Partnerships by Year, Pre-2011-2016
  • Figure 12.2 T-Cell Immunotherapy: Distribution of Partnerships by Type of Model
  • Figure 12.3 T-Cell Immunotherapy: Leading Industry Collaborators
  • Figure 12.4 T-Cell Immunotherapy: Leading Non-industry Collaborators
  • Figure 12.5 T-Cell Immunotherapy: Distribution of Partnerships by Type of Therapy
  • Figure 12.6 T-Cell Immunotherapy: Distribution of Partnerships by Product Therapy
  • Figure 13.1 T-Cell Immunotherapy: Funding Instances, Cumulative Number of Investments by Year, pre-2009-2016
  • Figure 13.2 T-Cell Immunotherapy: Funding Instances, Cumulative Distribution of Amount Invested by Year, pre-2009-2016 (USD Million)
  • Figure 13.3 T-Cell Immunotherapy: Funding Instances, Distribution of Instances by Type of Funding
  • Figure 13.4 T-Cell Immunotherapy: Funding Instances Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 14.1 Treg Cells: Functions
  • Figure 15.1 Cell Therapy Manufacturing: Key Steps
  • Figure 15.2 Cell Therapy Manufacturing: Scenarios
  • Figure 15.3 T-Cell Immunotherapy Manufacturing: Key Collaborations
  • Figure 17.1 Adaptimmune: Funding Instances (USD Million)
  • Figure 17.2 Altor Bioscience: Funding Instances (USD Million)
  • Figure 17.3 bluebird bio: Funding Instances (USD Million)
  • Figure 17.4 Cellectis: Funding Instances (USD Million)
  • Figure 17.5 CBMG: Funding Instances (USD Million)
  • Figure 17.6 Immunocore: Funding Instances (USD Million)
  • Figure 17.7 Juno Therapeutics: Funding Instances (USD Million)
  • Figure 17.8 Kite Pharma: Funding Instances (USD Million)
  • Figure 17.9 Lion Biotechnologies: Funding Instances (USD Million)
  • Figure 17.10 Novartis: Revenues 2011-9M 2016 (USD Billion)
  • Figure 17.11 Novartis: Distribution of Revenues by Operating Segments, 2015 (USD Billion)
  • Figure 17.12 Takara Bio: Revenues, 2011-2016 (JPY Billion)
  • Figure 17.13 Unum Therapeutics: Funding Instances (USD Million)
  • Figure 17.14 ACTR Technology: Treatment Process
  • Figure 19.1 T-Cell Immunotherapy Market Landscape: Industry Participants
  • Figure 19.2 T-Cell Immunotherapy Market Landscape: Non-industry Participants
  • Figure19.3 T-Cell Immunotherapy Market Forecast, 2018, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Million)

List of Tables

  • Table 3.1 FDA Approved Antibody Based Therapeutics for Cancer
  • Table 3.2 Retroviral Vectors: Salient Features
  • Table 3.3 Lentiviral Vectors: Salient Features
  • Table 4.1 CAR-T Cell Immunotherapy: Clinical Pipeline
  • Table 4.2 CAR-T Cell Immunotherapy: Preclinical / Discovery Pipeline
  • Table 4.3 TCR Cell Therapy: Clinical Pipeline
  • Table 4.4 TCR Cell Immunotherapy: Preclinical / Discovery Pipeline
  • Table 4.5 TIL Cell Immunotherapy: Clinical Pipeline
  • Table 4.6 TIL Cell Immunotherapy: Preclinical / Discovery Pipeline
  • Table 5.1 Key Characteristics of CAR-T cells
  • Table 5.2 Comparison Between 1st and 2nd Generation CARs
  • Table 5.3 Grading Criteria for CRS
  • Table 5.4 Safety Switches under Development for CART-T Therapy
  • Table 5.5 CD19 CAR-T Cells: Preclinical Results
  • Table 5.6 Other Targets under Clinical/Preclinical Studies for CAR-T Therapy
  • Table 5.7 CTL019: Clinical Studies
  • Table 5.8 CTL019: Clinical Trial Endpoints (ALL)
  • Table 5.9 CTL019: Clinical Trial Endpoints (CLL/MM/NHL)
  • Table 5.10 JCAR Series: Molecules in Clinical Development
  • Table 5.11 JCAR: CAR-T Design
  • Table 5.12 JCAR014: Current Status of Development
  • Table 5.13 JCAR015: Current Status of Development
  • Table 5.14 JCAR017: Current Status of Development
  • Table 5.15 JCAR018: Current Status of Development
  • Table 5.16 JCAR020: Current Status of Development
  • Table 5.17 JCAR023: Current Status of Development
  • Table 5.18 JCAR024: Current Status of Development
  • Table 5.19 JCAR Series: Clinical Trial Endpoints (Phase II)
  • Table 5.20 JCAR Series: Clinical Trial Endpoints (Phase I)
  • Table 5.21 JCAR: Dosage Regimen
  • Table 5.22 KTE-C19: Clinical Studies
  • Table 5.23 KTE-C19: Clinical Trial Endpoints
  • Table 5.24 KTE-C19: ZUMA-1 Phase II Results (≥3 months Follow-Up)
  • Table 5.25 KTE-C19: ZUMA-1 Phase I & Phase II Results (3 months Follow-Up)
  • Table 5.26 CBM CAR-T Series: Clinical Products,
  • Table 5.27 CBM-CD19.1 CAR-T: Clinical Studies
  • Table 5.28 CBM-CD20 CAR-T: Clinical Status
  • Table 5.29 CBM-CD30.1 CAR-T: Clinical Status
  • Table 5.30 CBM-EGFR.1 CAR-T: Clinical Status
  • Table 5.31 Cellular Biomedicine's CAR-T Series: Clinical Trial Endpoints
  • Table 5.32 CBM CAR-T Series: Patent Portfolio
  • Table 5.33 Takara Bio's CD19 CAR-T: Current Status of Development
  • Table 5.34 Takara Bio's CD19 CAR-T: Clinical Trial Endpoints
  • Table 6.1 CAR-T Cell and TCR Based Therapies: Key Differences
  • Table 6.2 NY-ESO TCR: Clinical Studies
  • Table 6.3 MAGE-A10: Clinical Studies
  • Table 6.4 NY-ESO TCR / MAGE A-10: Clinical Trial Endpoints
  • Table 6.5 ALT-801: Clinical Studies
  • Table 6.6 ALT-801: Clinical Trial Endpoints
  • Table 6.7 IMCgp100: Clinical Studies
  • Table 6.8 IMCgp100: Clinical Trial Endpoints
  • Table 6.9 JTCR016: Clinical Studies
  • Table 6.10 JTCR016: Clinical Trial Endpoints
  • Table 6.11 WT1 TCR: Clinical Studies
  • Table 6.12 WT1 TCR: Clinical Trial Endpoints
  • Table 7.1 LN-144: Clinical Trial Endpoints
  • Table 7.2 LN-144: Patent Portfolio
  • Table 7.3 Nantes University Hospital's TIL Therapy: Clinical Trial Endpoints
  • Table 7.4 Netherlands Cancer Institute's TIL Therapy: Clinical Trial Endpoints
  • Table 8.1 T-Cell Immunotherapy: List of Forecasted Molecules
  • Table 9.1 Comparison of Hodgkin's and Non-Hodgkin's Lymphoma
  • Table 9.2 Comparison of Marketed Targeted Therapeutics: Leukemia
  • Table 9.3 Comparison of Marketed Targeted Therapeutics: Lymphoma
  • Table 9.4 T-Cell Immunotherapy: Targets under Investigation for Leukaemia
  • Table 9.5 T-Cell Immunotherapy: Targets under Investigation for Lymphoma
  • Table 9.6 Comparison of Marketed Targeted Therapeutics: Multiple Myeloma
  • Table 9.7 T-Cell Immunotherapy: Targets under Investigation for Multiple Myeloma
  • Table 9.8 Comparison of Marketed Targeted Therapeutics: Melanoma
  • Table 9.9 TIL Therapy: Historical Development of Treatment Protocols at the National Cancer Institute
  • Table 9.10 Comparison of Marketed Therapeutics: Lung Cancer
  • Table 9.11 T-Cell Immunotherapy: Targets under Investigation for Lung Cancer
  • Table 9.12 Comparison of Marketed Targeted Therapeutics: Renal Cell Carcinoma
  • Table 9.13 T-Cell Immunotherapy: Targets under Investigation for Ovarian Cancer
  • Table 9.14 Comparison of Marketed Therapeutics: Breast Cancer
  • Table 9.15 T-Cell Immunotherapy: Targets under Investigation for Breast Cancer
  • Table 10.1 Editas Medicine: CRISPR/Cas9 Technology, Research Publications
  • Table 10.2 Editas Medicine: Funding Instances
  • Table 10.3 Editas Medicine: Collaborations
  • Table 10.4 Intellia Therapeutics: CRISPR/Cas9 Technology, Research Publications
  • Table 10.5 Intellia Therapeutics: Funding Instances
  • Table 10.6 Intellia Therapeutics: Collaborations
  • Table 10.7 CRISPR Therapeutics: CRIPSR/Cas9 Technology, Research Publications
  • Table 10.8 CRISPR Therapeutics: Funding Instances
  • Table 10.9 CRISPR Therapeutics: Collaborations
  • Table 10.10 Cellectis: Funding Instances
  • Table 10.11 Cellectis: Collaborations
  • Table 10.12 bluebird bio: Funding Instances
  • Table 10.13 bluebird bio: Collaborations
  • Table 10.14 Sangamo Biosciences: Funding Instances
  • Table 10.15 Sangamo Biosciences: Collaborations
  • Table 10.16 Unum Therapeutics: Funding Instances
  • Table 10.17 Unum Therapeutics: Collaborations
  • Table 10.18 Celyad: Funding Instances
  • Table 10.19 Celyad: Collaborations
  • Table 10.20 Intrexon: Funding Instances
  • Table 10.21 Intrexon: Collaborations
  • Table 10.22 Bellicum Pharmaceuticals: Key Switch Technologies
  • Table 10.23 Bellicum Pharmaceuticals: Switch Technologies, Research Publications
  • Table 10.24 Bellicum Pharmaceuticals: Funding Instances
  • Table 10.25 Bellicum Pharmaceuticals: Collaborations
  • Table 10.26 Theravectys: Funding Instances
  • Table 10.27 Formula Pharmaceuticals: Collaborations
  • Table 12.1 T-Cell Immunotherapy: Recent Collaborations
  • Table13.1 T-Cell Immunotherapy: List of Funding Rounds / Grants and Investors Involved
  • Table 14.1 List of Other Novel T-Cell Immunotherapies
  • Table 14.2 Treg Cell: Properties
  • Table 15.1 Cell Therapy Manufacturing: Companies with In-house Capabilities
  • Table 15.2 Cell Therapy Manufacturing: Contract Manufacturers
  • Table 16.1 Marketed Cell / Gene Therapies: Price
  • Table 16.2 Marketed Targeted Drugs for Cancer: Price
  • Table 16.3 T-Cell Immunotherapy: Expert Opinions on Pricing
  • Table 17.1 Adaptimmune: T-Cell Immunotherapy Pipeline
  • Table 17.2 Adaptimmune: T-Cell Immunotherapy Collaborations
  • Table 17.3 AltorBioScience: T-Cell Immunotherapy Pipeline
  • Table 17.4 AltorBioScience: T-Cell Immunotherapy Collaborations
  • Table 17.5 bluebird bio: T-Cell Immunotherapy Pipeline
  • Table 17.6 bluebird bio: T-Cell Immunotherapy Collaborations
  • Table 17.7 Cellectis: T-Cell Immunotherapy Pipeline
  • Table 17.8 Cellectis: T-Cell Immunotherapy Collaborations
  • Table 17.9 Cellular Biomedicine Group: T-Cell Immunotherapy Pipeline
  • Table 17.10 Cellular Biomedicine Group: T-Cell Immunotherapy Collaborations
  • Table 17.11 Immunocore: T-Cell Immunotherapy Pipeline
  • Table 17.12 Immunocore: T-Cell Immunotherapy Collaborations
  • Table 17.13 Juno Therapeutics: T-Cell Immunotherapy Pipeline
  • Table 17.14 Juno Therapeutics: T-Cell Immunotherapy Collaborations
  • Table 17.15 Kite Pharma: T-Cell Immunotherapy Pipeline
  • Table 17.16 Kite Pharma: T-Cell Immunotherapy Collaborations
  • Table 17.17 Lion Biotechnologies: T-Cell Immunotherapy Pipeline
  • Table 17.18 Lion Biotechnologies: T-Cell Immunotherapy Collaborations
  • Table 17.19 Novartis: T-Cell Immunotherapy Pipeline
  • Table 17.20 Novartis: T-Cell Immunotherapy Collaborations
  • Table 17.21 Takara Bio: T-Cell Immunotherapy Pipeline
  • Table 17.22 Takara Bio: T-Cell Immunotherapy Collaborations
  • Table 17.23 Unum Therapeutics: T-Cell Immunotherapy Pipeline
  • Table 17.24 Unum Therapeutics: T-Cell Immunotherapy Collaborations
  • Table 20.1 T-Cell Immunotherapy Pipeline: Distribution by Type of Product
  • Table 20.2 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer
  • Table 20.3 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer across CAR-Ts, TCRs and TILs
  • Table 20.4 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development
  • Table 20.5 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development across CAR-T, TCR and TIL
  • Table 20.6 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area
  • Table 20.7 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area across CAR-Ts, TCRs and TILs
  • Table 20.8 T-Cell Immunotherapy: Popular Target Indications
  • Table 20.9 CAR-T Cell Immunotherapy: Popular Target Indications
  • Table 20.10 TCR Cell Immunotherapy: Popular Target Indications
  • Table 20.11 TIL Cell Immunotherapy: Popular Target Indications
  • Table 20.12 T-Cell Immunotherapy Pipeline: Active Industry Players in Clinical Development
  • Table 20.13 T-Cell Immunotherapy Pipeline: Active Industry Players in Preclinical Development
  • Table 20.14 T-Cell Immunotherapy Pipeline: Active Non-Industry Players
  • Table 20.15 CAR-T Cell Therapy Pipeline: Distribution by Target Antigen
  • Table 20.16 TCR Therapy Pipeline: Distribution by Target Antigen
  • Table 20.17 Overall T-Cell Immunotherapy Market (Till 2030): Conservative Scenario (USD Billion)
  • Table 20.18 Overall T-Cell Immunotherapy Market(Till 2030): Base Scenario (USD Billion)
  • Table 20.19 Overall T-Cell Immunotherapy Market(Till 2030): Optimistic Scenario (USD Billion)
  • Table 20.20 T-Cell Therapy Market, 2020, 2025 and 2030: Conservative Scenario (USD Million)
  • Table 20.21 T-Cell Therapy Market, 2020, 2025 and 2030: Base Scenario (USD Million)
  • Table 20.22 T-Cell Therapy Market, 2020, 2025 and 2030: Optimistic Scenario (USD Million)
  • Table 20.23 Overall CAR-T Market Forecast(Till 2030): Conservative Scenario (USD Billion)
  • Table 20.24 Overall CAR-T Market Forecast (Till 2030): Base Scenario (USD Billion)
  • Table 20.25 Overall CAR-T Market Forecast (Till 2030): Optimistic Scenario (USD Billion)
  • Table 20.26 CTL019 Sales Forecast(Till 2030): Conservative Scenario (USD Million
  • Table 20.27 CTL019 Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Table 20.28 CTL019 Sales Forecast(Till 2030): Optimistic Scenario (USD Million
  • Table 20.29 KTE-C19 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.30 KTE-C19 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.31 KTE-C19 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
  • Table 20.32 JCAR015 Sales Forecast(Till 2030): Conservative Scenario (USD Million)
  • Table 20.33 JCAR015 Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Table 20.34 JCAR015 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.35 CBM-CD30 CAR-T Sales Forecast(Till 2030): Conservative Scenario (USD Million)
  • Table 20.36 CBM-CD30 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Table 20.37 CBM-CD30 CAR-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.38 CBM-CD20 CAR-T Sales Forecast(Till 2030): Conservative Scenario (USD Million)
  • Table 20.39 CBM-CD20 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Table 20.40 CBM-CD20 CAR-T Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
  • Table 20.41 CBM-EGFR CAR-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.42 CBM-EGFR CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Table 20.43 CBM-EGFR CAR-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.44 Sinobioway Cell Therapy's CD 19 CAR-T Sales Forecast(Till 2030): Conservative Scenario (USD Million)
  • Table 20.45 Sinobioway Cell Therapy's CD 19CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Table 20.46 Sinobioway Cell Therapy's CD 19 CAR-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.47 Takara Bio's CD 19 CAR-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.48 Takara Bio's CD 19CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.49 Takara Bio's CD 19 CAR-T Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
  • Table 20.50 GPC3 CAR-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.51 GPC3 CAR-T Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Table 20.52 GPC3 CAR-T Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
  • Table 20.53 JCAR017 Sales Forecast, (Till 2030): Conservative Scenario (USD Million)
  • Table 20.54 JCAR017 Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Table 20.55 JCAR017 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.56 Overall TCR Market Forecast(Till 2030): Conservative Scenario (USD Million)
  • Table 20.57 Overall TCR Market Forecast(Till 2030): Base Scenario (USD Million)
  • Table 20.58 Overall TCR Market Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.59 IMCgp100 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
  • Table 20.60 IMCgp100 Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Table 20.61 IMCgp100 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
  • Table 20.62 HPV-16E6-TCR Sales Forecast(Till 2030): Conservative Scenario (USD Million)
  • Table 20.63 HPV-16E6-TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.64 HPV-16E6-TCR Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
  • Table 20.65 NY-ESO-1 TCR Sales Forecast(Till 2030): Conservative Scenario (USD Million)
  • Table 20.66 NY-ESO-1 TCR Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Table 20.67 NY-ESO-1 TCR Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.68 HBV antigen specific TCR Sales Forecast(Till 2030): Conservative Scenario (USD Million)
  • Table 20.69 HBV antigen specific TCR Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Table 20.70 HBV antigen specific TCR Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.71 ALT-801 Sales Forecast(Till 2030): Conservative Scenario (USD Million)
  • Table 20.72 ALT-801 Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Table 20.73 ALT-801 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
  • Table 20.74 JTCR016 Sales Forecast(Till 2030): Conservative Scenario (USD Million)
  • Table 20.75 JTCR016 Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Table 20.76 JTCR016 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
  • Table 20.77 KITE-718 (MAGE A3/A6) Sales Forecast(Till 2030): Conservative Scenario (USD Million)
  • Table 20.78 KITE-718 (MAGE A3/A6) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.79 KITE-718 (MAGE A3/A6) Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
  • Table 20.80 MAGE A3 Sales Forecast(Till 2030): Conservative Scenario (USD Million)
  • Table 20.81 MAGE A3 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.82 MAGE A3 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
  • Table 20.83 WT-1 TCR Sales Forecast(Till 2030): Conservative Scenario (USD Million)
  • Table 20.84 WT-1 TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.85 WT-1 TCR Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.86 MAGE A-10 TCR Sales Forecast(Till 2030): Conservative Scenario (USD Million)
  • Table 20.87 MAGE A-10 TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 20.88 MAGE A-10 TCR Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
  • Table 20.89 Overall TIL Market Forecast(Till 2030): Conservative Scenario (USD Billion)
  • Table 20.90 Overall TIL Market Forecast (Till 2030): Base Scenario (USD Billion)
  • Table 20.91 Overall TIL Market Forecast(Till 2030): Optimistic Scenario (USD Billion)
  • Table 20.92 LN-144 Sales Market Forecast(Till 2030): Conservative Scenario (USD Million)
  • Table 20.93 LN-144 Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Table 20.94 LN-144 Sales Forecast(Till 2030): Optimistic Scenario (USD Million)
  • Table 20.95 Nantes University Hospital's TIL Therapy Sales Forecast(Till 2030): Conservative Scenario (USD Million)
  • Table 20.96 Nantes University Hospital's TIL Therapy Sales Forecast(Till 2030): Base Scenario (USD Million)
  • Table 20.97 Nantes University Hospital's TIL Therapy Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
  • Table 20.98 Netherland Cancer Institute's TIL Therapy Sales Market Forecast, 2018-2030: Conservative Scenario (USD Million)
  • Table 20.99 Netherland Cancer Institute's TIL Therapy Sales Forecast, 2018-2030: Base Scenario (USD Million)
  • Table 20.100 Netherland Cancer Institute's TIL Therapy Sales Forecast, 2018-2030: Optimistic Scenario (USD Million)
  • Table 20.101 T-Cell Immunotherapy: Cumulative Distribution of Partnerships by Year, Pre-2011-2016
  • Table 20.102 T-Cell Immunotherapy: Distribution of Partnerships by Type of Model
  • Table 20.103 T-cell Immunotherapy: Leading Industry Collaborators
  • Table 20.104 T-cell immunotherapy: Leading Non-industry Collaborators
  • Table 20.105 T-Cell Immunotherapy: Distribution of Partnerships by Type of Therapy
  • Table 20.106 T-Cell Immunotherapy: Distribution of Partnerships by Product Therapy
  • Table 20.107 T-Cell Immunotherapy: Funding Instances, Cumulative Number of Investments by Year, pre-2009-2016
  • Table 20.108 T-Cell Immunotherapy: Funding Instances, Cumulative Distribution of Amount Invested by Year, pre-2009-2016 (USD Million)
  • Table 20.109 T-Cell Immunotherapy: Funding Instances, Distribution of Instances by Type of Funding
  • Table 20.110 T-Cell Immunotherapy: Funding Instances Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 20.111 Adaptimmune: Funding Instances (USD Million)
  • Table 20.112 AltorBioScience: Funding Instances (USD Million)
  • Table 20.113 blubird bio: Funding Instances (USD Million)
  • Table 20.114 Cellectis: Funding Instances (USD Million)
  • Table 20.115 Cellular Biomedicine Group: Funding Instances (USD Million)
  • Table 20.116 Immunocore: Funding Instances (USD Million)
  • Table 20.117 Juno Therapeutics: Funding Instances (USD Million)
  • Table 20.118 Kite Pharma: Funding Instances (USD Million)
  • Table 20.119 Lion Biotechnologies: Funding Instances (USD Million)
  • Table 20.120 Novartis: Revenues 2011-9M 2016 (USD Billion)
  • Table 20.121 Novartis: Distribution of Revenues by Operating Segments, 2015 (USD Billion)
  • Table 20.122 Takara Bio: Revenues, 2011-2016 (JPY Million)
  • Table 20.123 Unum Therapeutics: Funding Instances (USD Million)
  • Table 20.124 T-Cell Immunotherapy Market Forecast: Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1. AbbVie
  • 2. Abingworth
  • 3. AbraxisBioScience
  • 4. AbVitro
  • 5. Adaptimmune
  • 6. Adicet Bio
  • 7. Advanced BioScience Laboratories
  • 8. Adverum Biotechnologies
  • 9. Affiliated Hospital to Academy of Military Medical Sciences
  • 10. AGF Private Equity
  • 11. AgonOx
  • 12. Agreen Biotech
  • 13. AJU IB Investment
  • 14. Alaska Permanent Fund
  • 15. Albert Einstein College of Medicine
  • 16. Alexandria Ventures
  • 17. Alexion Pharmaceuticals
  • 18. Allen Laboratories
  • 19. Allos Therapeutics
  • 20. Alpine Immune Sciences
  • 21. Alta Partners
  • 22. AltorBioScience
  • 23. Amgen
  • 24. Amsterdam BioTherapeutics Unit
  • 25. Antoni van Leeuwenhoek Hospital
  • 26. apcethBiopharma
  • 27. Aquilo Capital Management
  • 28. ARCH Venture Partners
  • 29. Argos Therapeutics
  • 30. ArtaxBioPharma
  • 31. Astellas Pharma
  • 32. AstraZeneca
  • 33. Asymptote
  • 34. Atara Biotherapeutics
  • 35. Atlantic Bio GMP
  • 36. Atlas Venture
  • 37. Atreca Therapeutics
  • 38. AURORA BioPharma
  • 39. Autolus
  • 40. AVG Ventures
  • 41. Avidex
  • 42. BankInvest Biomedical Venture
  • 43. Batavia Biosciences
  • 44. Bavarian Nordic
  • 45. Baxalta
  • 46. Bayer
  • 47. Bayer Crop Sciences
  • 48. Baylor College of Medicine
  • 49. Beijing Doing Biomedical
  • 50. Bellicum Pharmaceuticals
  • 51. Bezos Expeditions
  • 52. Bill & Melinda Gates Foundation
  • 53. Bio Elpida
  • 54. Biogen
  • 55. BioLife Solutions
  • 56. Biomedical Catalyst
  • 57. Biomedical Catalyst Fund
  • 58. BioNTech
  • 59. Biotecnol
  • 60. BioVeda China Fund
  • 61. bluebird bio
  • 62. Boehringer Ingelheim
  • 63. Boston Children's Hospital
  • 64. Bpifrance
  • 65. Brace Pharma Capital
  • 66. Breast International Group
  • 67. Bristol-Myers Squibb
  • 68. Broad Institute
  • 69. Broadfin Capital
  • 70. Cabaret Biotech
  • 71. Caladrius Biosciences
  • 72. California Institute for Regenerative Medicine
  • 73. Cancer Prevention and Research Institute of Texas
  • 74. Cancer Research UK
  • 75. Cardiff University
  • 76. Caribou Biosciences
  • 77. CARsgen Therapeutics
  • 78. Cartherics
  • 79. Casdin Capital
  • 80. Celgene
  • 81. Cell and Gene Therapy Catapult
  • 82. Cell Design Labs
  • 83. Cell Medica
  • 84. Cell Therapies
  • 85. Cell Therapy and Cell Engineering Facility
  • 86. Cellectis
  • 87. CELLforCURE
  • 88. Cellular Biomedicine Group
  • 89. Cellular Therapeutics
  • 90. Celyad
  • 91. Centre for Cell Manufacturing Ireland
  • 92. Changzheng Hospital
  • 93. Charité - Universitätsmedizin Berlin
  • 94. CHDI Foundation
  • 95. Chengdu MedGenCell
  • 96. Children's Hospital of Philadelphia
  • 97. Children's Mercy Hospital Kansas City
  • 98. Chimeric Therapeutics
  • 99. Chinese PLA General Hospital
  • 100. Christie NHS Foundation Trust
  • 101. Chugai Seiyaku Kabushiki Kaisha
  • 102. City of Hope Medical Center
  • 103. Clough Capital Partners
  • 104. Cognate Bioservices
  • 105. Cold Genesys
  • 106. Columbia University
  • 107. Cooperative Research Center for Cell Therapy Manufacturing
  • 108. Corixa
  • 109. Cowen Group Investment
  • 110. CRISPR Therapeutics
  • 111. Cystic Fibrosis Foundation Therapeutics
  • 112. Cytolumina Technologies
  • 113. Cytovance Biologics
  • 114. Dana-Farber Cancer Institute
  • 115. Dangdai International
  • 116. Dartmouth College
  • 117. Deerfield Management
  • 118. Delenex Therapeutics
  • 119. Dendreon
  • 120. Duke University
  • 121. Dutch Cancer Society
  • 122. Easton Capital
  • 123. EcoR1 Capital
  • 124. Editas Medicine
  • 125. Edmond Venture Capital
  • 126. Eisai
  • 127. Eli Lilly
  • 128. Endocyte
  • 129. Erasmus University Medical Center
  • 130. ERS Genomics
  • 131. EUFETS
  • 132. Eureka Therapeutics
  • 133. Fate Therapeutics
  • 134. FCB-Pharmicell
  • 135. Fetolumina Technologies
  • 136. FGP Capital
  • 137. Fidelity Biosciences
  • 138. Fidelity Management & Research Company
  • 139. Financière IDAT
  • 140. Finnish Innovation Fund
  • 141. Five Prime Therapeutics
  • 142. Flagship Ventures
  • 143. Fondazione Telethon
  • 144. Forbion Capital Partners
  • 145. Foresite Capital
  • 146. Formula Pharmaceuticals
  • 147. Fortress Biotech
  • 148. Franklin Templeton Investments
  • 149. FraunhoferInsitute for Cell Therapy and Immunology
  • 150. Fred Hutchinson Cancer Research Center
  • 151. Fuda Cancer Hospital
  • 152. Gadeta
  • 153. GammaCell Bio-Technologies
  • 154. GE Global Research
  • 155. Gene and Cell Therapy Lab
  • 156. Genentech
  • 157. Généthon
  • 158. GigaGen
  • 159. Gilead Sciences
  • 160. GlaxoSmithKline
  • 161. Google Ventures
  • 162. Great Ormond Street Hospital
  • 163. Green Cross Cell
  • 164. Griffin Securities
  • 165. Guy's and St Thomas' NHS Foundation Trust
  • 166. H. Lee Moffitt Cancer Center and Research Institute Hospital
  • 167. Hadassah Medical Organization
  • 168. Harvard University
  • 169. Heat Biologics
  • 170. Herlev Hospital
  • 171. Howard Hughes Medical Institute
  • 172. iCarTABBioMed
  • 173. iCell Therapeutics
  • 174. ImClone Systems
  • 175. Immatics
  • 176. Immune Therapeutics
  • 177. Immunex
  • 178. ImmunoCellular Therapeutics
  • 179. Immunocore
  • 180. Immunovative Therapies
  • 181. Imperial College London
  • 182. Imperial Innovations
  • 183. Innovative Cellular Therapeutics
  • 184. Innovative Genome Initiative
  • 185. Institut Curie (Curie Institute)
  • 186. Institut Pasteur (Pasteur Institute)
  • 187. Institute of Translational Health Sciences
  • 188. Intellia Therapeutics
  • 189. Intrexon
  • 190. Iowa State University
  • 191. Janssen Biotech
  • 192. Janus Capital Group
  • 193. JCR Pharmaceutical
  • 194. Jennison Associates
  • 195. JIC GenesisFountain Healthcare Ventures
  • 196. Jichi Medical University Hospital
  • 197. JMP Securities
  • 198. John Wayne Cancer Institute
  • 199. Johns Hopkins Kimmel Cancer Center
  • 200. Johns Hopkins University
  • 201. Johnson & Johnson
  • 202. Jolly Innovation Ventures
  • 203. Juno Therapeutics
  • 204. JW Biotechnology
  • 205. Kaitai Capital
  • 206. Karolinska University Hospital
  • 207. Keio University School of Medicine
  • 208. Khosla Ventures
  • 209. King's College London- Rayne Cell Therapy Suite
  • 210. Kite Pharma
  • 211. KTB Ventures
  • 212. Leiden University Medical Center
  • 213. Leucid Bio
  • 214. Lifeline Ventures Fund
  • 215. Ligand Pharmaceuticals
  • 216. Lilly Asia Ventures
  • 217. Lion Biotechnologies
  • 218. Lion TCR
  • 219. Lonza Biologics
  • 220. Loyola University
  • 221. Lymphoma and Leukemia Society
  • 222. MabQuest
  • 223. Malin Corporation
  • 224. Massachusetts General Hospital
  • 225. MaSTherCell
  • 226. Max DelbrückCenter for Molecular Medicine
  • 227. MaxCyte
  • 228. Mayo Clinic
  • 229. MD Anderson Cancer Center
  • 230. Medarex
  • 231. Medicxi Ventures
  • 232. Medigene
  • 233. MedImmune
  • 234. MedPost Urgent Care
  • 235. Memorial Sloan Kettering Cancer Center
  • 236. Merck
  • 237. Merck Serono
  • 238. Merlin Nexus
  • 239. Mie University
  • 240. Millennium Pharmaceuticals
  • 241. MiltenyiBiotec
  • 242. Mission Bay Capital
  • 243. Molecular and Cellular Therapeutics
  • 244. MolMed
  • 245. Morphotek
  • 246. Mustang Bio
  • 247. Nantes University Hospital
  • 248. NantKwest (earlier Conkwest)
  • 249. NantWorks
  • 250. National Cancer Institute
  • 251. National Institute of Allergy and Infectious Diseases
  • 252. National Institutes of Health
  • 253. National University of Ireland
  • 254. National University of Singapore
  • 255. Netherlands Cancer Institute
  • 256. New Enterprise Associates
  • 257. New Leaf Venture Partners
  • 258. New River Management
  • 259. NewVa Capital Partners
  • 260. NIHR Oxford Biomedical Research Centre
  • 261. Novartis
  • 262. Novartis Venture Fund
  • 263. Novo Ventures
  • 264. Oberland Capital
  • 265. ODYSSEE Venture
  • 266. Ohio State University
  • 267. Omega Funds
  • 268. Oncodesign Biotechnology
  • 269. OnCyte
  • 270. ONO Pharmaceutical
  • 271. Onyx Pharmaceuticals
  • 272. Opexa Therapeutics
  • 273. Opus Bio
  • 274. OrbiMed
  • 275. OSEO
  • 276. OspedalePediatrico Bambino Gesù (Bambino Gesù Children's Hospital)
  • 277. Ospedale San Raffaele (San Raffaele Hospital)
  • 278. Oxford BioMedica
  • 279. Partners Innovation Fund
  • 280. Peking University
  • 281. Perceptive Bioscience Investments
  • 282. PersonGen Biomedicine (Suzhou)
  • 283. Peter MacCallum Cancer Centre
  • 284. Pfizer
  • 285. PharmaCell
  • 286. Pharmacyclics
  • 287. Pierre Fabre Group
  • 288. PLA General Hospital
  • 289. Polaris Partners
  • 290. PolyBioCept
  • 291. Pontifax
  • 292. Poseida Therapeutics
  • 293. Precision BioSciences
  • 294. Pregenen
  • 295. Progenitor Cell Therapy
  • 296. Prometheus Laboratories
  • 297. QueensBridge Venture Partners
  • 298. Quogue Capital
  • 299. QVT Financial
  • 300. RA Capital Management
  • 301. Ramius Capital Group
  • 302. Redmile Group
  • 303. RedoxTherapies
  • 304. Regeneron Pharmaceuticals
  • 305. Remeditex Ventures
  • 306. Renji Hospital
  • 307. Ridgeback Capital Management
  • 308. Ridgeway Capital Partners
  • 309. Riverbank Capital Securities
  • 310. Roche
  • 311. Rock Springs Capital
  • 312. Rockland Immunochemicals
  • 313. Roger Williams Medical Center
  • 314. Roswell Park Cancer Institute
  • 315. Royal Adelaide Hospital Cancer Center
  • 316. Sabby Management
  • 317. Sanford Research
  • 318. SangamoBioSciences
  • 319. Sanofi Aventis
  • 320. Sanofi-Genzyme BioVentures
  • 321. Schering-Plough
  • 322. Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility
  • 323. Seattle Children's Hospital
  • 324. Seattle Genetics
  • 325. Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
  • 326. Second Military Medical University
  • 327. Sectoral Asset Management
  • 328. Servier
  • 329. Shanghai Cancer Institute
  • 330. Shanghai Chest Hospital
  • 331. Shanghai Genechem
  • 332. Sheba Medical Center
  • 333. Shenzhen Institute for Innovation and Translational Medicine
  • 334. Shenzhen Second People's Hospital
  • 335. Shionogi
  • 336. Sichuan University
  • 337. Sidney Kimmel Comprehensive Cancer Center
  • 338. Sinobioway Cell Therapy
  • 339. SOLTI Breast Cancer Research Group
  • 340. Sorrento Therapeutics
  • 341. SOTIO
  • 342. Southwest Hospital
  • 343. Spectrum Pharmaceuticals
  • 344. SR One
  • 345. St. Jude Children's Research Hospital
  • 346. Stage Cell Therapeutics
  • 347. Stanford University
  • 348. Stifel
  • 349. Sun Yat-Sen University
  • 350. Super-T Cell Cancer Company
  • 351. Syncona
  • 352. T. Rowe Price Associates
  • 353. Takara Biosciences
  • 354. Targazyme
  • 355. T-Cell Factory
  • 356. Techno Venture Management
  • 357. Tel Aviv Sourasky Medical Center
  • 358. Terumo
  • 359. Tessa Therapeutics
  • 360. Tethys Holdings
  • 361. Texas Emerging Technology Fund
  • 362. The Clinical Cell and Vaccine Production Facility
  • 363. Theravectys
  • 364. Thermo Fisher Scientific
  • 365. Third Military Medical University
  • 366. Third Rock Ventures
  • 367. Third Security
  • 368. Three Arch Opportunity Fund
  • 369. Tianjin Medical University Cancer Institute and Hospital
  • 370. TiGenix
  • 371. TILT Biotherapeutics
  • 372. Tmunity Therapeutics
  • 373. TNK Therapeutics
  • 374. Tongji Hospital
  • 375. Tongji University School of Medicine
  • 376. TRACT Therapeutics
  • 377. Transposagen Biopharmaceuticals
  • 378. TriumviraImmunologics
  • 379. TVAX Biomedical
  • 380. TVM Capital
  • 381. Two Blades Foundation
  • 382. TxCell
  • 383. UCLA Jonsson Comprehensive Cancer Center
  • 384. UNC Lineberger Comprehensive Cancer Center
  • 385. uniQure
  • 386. United Therapeutics
  • 387. Universal Cells
  • 388. University College London
  • 389. University Health Network, Toronto
  • 390. University Medical Center Utrecht
  • 391. University of Birmingham
  • 392. University of California, Berkeley
  • 393. University of Florida
  • 394. University of Lausanne
  • 395. University of Milano-Bicocca
  • 396. University of Minnesota
  • 397. University of Oxford
  • 398. University of Pennsylvania
  • 399. University of Zurich
  • 400. Unum Therapeutics
  • 401. Uppsala University
  • 402. Utrecht Holdings
  • 403. Vaccinogen
  • 404. Valeant Pharmaceuticals
  • 405. venBio
  • 406. Venrock
  • 407. Versant Ventures
  • 408. Vertex
  • 409. VGXI
  • 410. Vical
  • 411. Viking Global Investors
  • 412. ViroMed
  • 413. VorBiopharma
  • 414. Weill Cornell Graduate School of Medical Sciences
  • 415. Wellington Management
  • 416. West China Hospital
  • 417. Woodford Investment Management
  • 418. Wunderlich
  • 419. WuXiAppTec
  • 420. Wyeth (Pfizer)
  • 421. X-Body
  • 422. Xijing Hospital
  • 423. Xinqiao Hospital
  • 424. Xuzhou Medical College
  • 425. Zhujiang Hospital
  • 426. ZIOPHARM Oncology
Back to Top